inclusion criteria: * male or female, ≥ 16 years old at day 0. * willing to provide consent indicating that she or he understands the purpose and potential risks and is willing and able to participate in the study and comply with all the study requirements and procedures. * have a recognized primary vaccination scheme recognized by the authorities with comirnaty, spikevax, vaxevria or janssen at least 91 days and preferably a maximum of 240 days before day 0. * if having an underlying illnesses must be stable and well-controlled according to the investigator judgment. * participant is willing to avoid receiving live attenuated vaccines (licensed) within 4 weeks before screening or after receiving any study vaccine, or other not live vaccines (licensed) within 14 days before and after receiving any study vaccine. * participant agrees not to donate blood, blood products and bone marrow at least 3 months before and after vaccination. * female participant of childbearing potential must have a negative pregnancy test on the on day 0 prior to vaccination. * female participant of childbearing potential must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (hormonal contraception: oral, injectable or transdermal patch, intrauterine device, vasectomized partner, sexual abstinence or condom). * male participants must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (vasectomized participants, condom, sexual abstinence). * male participants must refrain from donating sperm for at least 28 days after day 0.

inclusion criteria: * male or female, ≥ 16 years old at day 0. * willing to provide consent indicating that she or he understands the purpose and potential risks and is willing and able to participate in the study and comply with all the study requirements and procedures. * have a recognized primary vaccination scheme recognized by the authorities with comirnaty, spikevax, vaxevria or janssen at least 91 days and preferably a maximum of 240 days before day 0. * if having an underlying illnesses must be stable and well-controlled according to the investigator judgment. * participant is willing to avoid receiving live attenuated vaccines (licensed) within 4 weeks before screening or after receiving any study vaccine, or other not live vaccines (licensed) within 14 days before and after receiving any study vaccine. * participant agrees not to donate blood, blood products and bone marrow at least 3 months before and after vaccination. * female participant of childbearing potential must have a negative pregnancy test on the on day 0 prior to vaccination. * female participant of childbearing potential must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (hormonal contraception: oral, injectable or transdermal patch, intrauterine device, vasectomized partner, sexual abstinence or condom). * male participants must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (vasectomized participants, condom, sexual abstinence). * male participants must refrain from donating sperm for at least 28 days after day 0.

inclusion criteria: male or female, ≥ 16 years old at day 0. willing to provide consent indicating that she or he understands the purpose and potential risks and is willing and able to participate in the study and comply with all the study requirements and procedures. have a recognized primary vaccination scheme recognized by the authorities with comirnaty, spikevax, vaxevria or janssen at least 91 days and preferably a maximum of 240 days before day 0. if having an underlying illnesses must be stable and well-controlled according to the investigator judgment. participant is willing to avoid receiving live attenuated vaccines (licensed) within 4 weeks before screening or after receiving any study vaccine, or other not live vaccines (licensed) within 14 days before and after receiving any study vaccine. participant agrees not to donate blood, blood products and bone marrow at least 3 months before and after vaccination. female participant of childbearing potential must have a negative pregnancy test on the on day 0 prior to vaccination. female participant of childbearing potential must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (hormonal contraception: oral, injectable or transdermal patch, intrauterine device, vasectomized partner, sexual abstinence or condom). male participants must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (vasectomized participants, condom, sexual abstinence). male participants must refrain from donating sperm for at least 28 days after day 0.

inclusion criteria: male or female, ≥ 16 years old at day 0. willing to provide consent indicating that she or he understands the purpose and potential risks and is willing and able to participate in the study and comply with all the study requirements and procedures. have a recognized primary vaccination scheme recognized by the authorities with comirnaty, spikevax, vaxevria or janssen at least 91 days and preferably a maximum of 240 days before day 0. if having an underlying illnesses must be stable and well-controlled according to the investigator judgment. participant is willing to avoid receiving live attenuated vaccines (licensed) within 4 weeks before screening or after receiving any study vaccine, or other not live vaccines (licensed) within 14 days before and after receiving any study vaccine. participant agrees not to donate blood, blood products and bone marrow at least 3 months before and after vaccination. female participant of childbearing potential must have a negative pregnancy test on the on day 0 prior to vaccination. female participant of childbearing potential must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (hormonal contraception: oral, injectable or transdermal patch, intrauterine device, vasectomized partner, sexual abstinence or condom). male participants must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (vasectomized participants, condom, sexual abstinence). male participants must refrain from donating sperm for at least 28 days after day 0.